Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
| All Releases |
|---|
 |
AlgoRx and Corgentech to Webcast Presentation From the Lazard Capital Markets 2005 Life Sciences Conference
Nov 22, 2005
|
68.5 KB
|
| |
SECAUCUS, N.J. and SOUTH SAN FRANCISCO, Calif., Nov 22, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- AlgoRx Pharmaceuticals, Inc. and Corgentech Inc. (Nasdaq: CGTK), today announced that John P. McLaughlin, Corgentech's chief executive officer, will present at the Lazard Capital Markets 2005 Life Sciences Conference on November 30, 2005 ...
|
|
|
AlgoRx and Corgentech to Mail Definitive Proxy for Proposed Merger
Nov 17, 2005
|
72.7 KB
|
| |
SECAUCUS, N.J. and SOUTH SAN FRANCISCO, Calif., Nov 17, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- AlgoRx Pharmaceuticals, Inc. and Corgentech Inc. (Nasdaq: CGTK) today announced that the joint proxy statement/prospectus in connection with the merger transaction involving Corgentech and AlgoRx is being mailed to both companies' stockho...
|
|
|
AlgoRx and Corgentech Announce Addition of Ninth Board Member to Proposed Board of Directors for Combined Company
Nov 15, 2005
|
72.7 KB
|
| |
SECAUCUS, N.J. and SOUTH SAN FRANCISCO, Calif., Nov 15, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- AlgoRx Pharmaceuticals, Inc. and Corgentech Inc. (Nasdaq: CGTK) today announced that Robert L. Zerbe, M.D. has been proposed as the ninth board member for the combined company. Dr. Zerbe, who has overseen successful clinical development p...
|
|
|
AlgoRx and Corgentech Announce Positive Data From Second of Two Phase 3 Trials of ALGRX 3268
Nov 8, 2005
|
78.9 KB
|
| |
SECAUCUS, N.J. and SOUTH SAN FRANCISCO, Calif., Nov 08, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- AlgoRx Pharmaceuticals, Inc. and Corgentech Inc. (Nasdaq: CGTK) today announced positive data from the second of two Phase 3 trials of ALGRX 3268 -- a fast-acting local anesthetic administered into the skin by powder injection and aimed a...
|
|
|
AlgoRx and Corgentech to Webcast Presentations From Two Upcoming Investor Conferences
Nov 2, 2005
|
70.8 KB
|
| |
SECAUCUS, N.J. and SOUTH SAN FRANCISCO, Calif., Nov 02, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- AlgoRx Pharmaceuticals, Inc. and Corgentech Inc. (Nasdaq: CGTK), today announced that John P. McLaughlin, Corgentech's chief executive officer, has been invited to present at two upcoming investor conferences. Each of the presentations wi...
|
|
|
Click here to download our most recent fact sheet.